| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Electrocardiography | 115 | 1994 | 132 |
Why?
|
Long QT Syndrome | 84 | 1994 | 35 |
Why?
|
Defibrillators, Implantable | 78 | 2000 | 35 |
Why?
|
Myocardial Infarction | 78 | 1994 | 129 |
Why?
|
Heart Rate | 59 | 1995 | 138 |
Why?
|
Tachycardia, Ventricular | 37 | 1994 | 25 |
Why?
|
Death, Sudden, Cardiac | 59 | 1994 | 31 |
Why?
|
Electrocardiography, Ambulatory | 36 | 1990 | 23 |
Why?
|
Heart Conduction System | 26 | 1994 | 37 |
Why?
|
Heart Failure | 28 | 2004 | 106 |
Why?
|
Ventricular Dysfunction, Left | 26 | 2001 | 35 |
Why?
|
Arrhythmias, Cardiac | 27 | 1994 | 65 |
Why?
|
Risk Assessment | 55 | 2001 | 324 |
Why?
|
Humans | 281 | 1986 | 1856 |
Why?
|
Cardiac Resynchronization Therapy | 10 | 2010 | 8 |
Why?
|
Arrhythmogenic Right Ventricular Dysplasia | 11 | 2003 | 7 |
Why?
|
Male | 209 | 1986 | 1553 |
Why?
|
Risk Factors | 90 | 1994 | 555 |
Why?
|
Female | 202 | 1986 | 1643 |
Why?
|
Diagnosis, Computer-Assisted | 8 | 2005 | 39 |
Why?
|
Genetic Predisposition to Disease | 23 | 1999 | 131 |
Why?
|
Ventricular Fibrillation | 15 | 2003 | 24 |
Why?
|
Ether-A-Go-Go Potassium Channels | 11 | 2002 | 9 |
Why?
|
Middle Aged | 129 | 1986 | 1161 |
Why?
|
Coronary Artery Disease | 11 | 2003 | 56 |
Why?
|
Electric Countershock | 13 | 2004 | 24 |
Why?
|
Mutation | 26 | 1995 | 340 |
Why?
|
Coronary Disease | 17 | 1990 | 94 |
Why?
|
Aged | 94 | 1986 | 988 |
Why?
|
Survival Analysis | 37 | 1997 | 205 |
Why?
|
Myocardial Ischemia | 13 | 1994 | 62 |
Why?
|
Prognosis | 43 | 1994 | 388 |
Why?
|
Cardiac Pacing, Artificial | 8 | 2005 | 27 |
Why?
|
Proportional Hazards Models | 50 | 1998 | 123 |
Why?
|
Anti-Arrhythmia Agents | 10 | 1994 | 36 |
Why?
|
Treatment Outcome | 43 | 2001 | 661 |
Why?
|
Adrenergic beta-Antagonists | 25 | 1998 | 47 |
Why?
|
KCNQ1 Potassium Channel | 12 | 2002 | 13 |
Why?
|
Adult | 102 | 1986 | 1317 |
Why?
|
Stroke Volume | 22 | 2002 | 54 |
Why?
|
Genotype | 34 | 1995 | 175 |
Why?
|
Atrial Fibrillation | 8 | 2003 | 40 |
Why?
|
Follow-Up Studies | 50 | 1994 | 553 |
Why?
|
Heart Diseases | 8 | 1991 | 92 |
Why?
|
Sodium Channels | 9 | 1998 | 32 |
Why?
|
Sotalol | 6 | 2003 | 6 |
Why?
|
Tachycardia, Sinus | 3 | 1997 | 5 |
Why?
|
Polymorphism, Genetic | 7 | 2001 | 94 |
Why?
|
Torsades de Pointes | 8 | 1997 | 16 |
Why?
|
Heart Arrest | 19 | 1994 | 37 |
Why?
|
Algorithms | 10 | 2003 | 226 |
Why?
|
Signal Processing, Computer-Assisted | 13 | 1995 | 39 |
Why?
|
Coronary Artery Bypass | 4 | 2003 | 46 |
Why?
|
Ventricular Premature Complexes | 7 | 2003 | 11 |
Why?
|
Pacemaker, Artificial | 6 | 2004 | 29 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2003 | 176 |
Why?
|
Syncope | 21 | 1994 | 24 |
Why?
|
Potassium Channels, Voltage-Gated | 6 | 2002 | 17 |
Why?
|
Cardiomyopathy, Dilated | 7 | 1994 | 24 |
Why?
|
Time Factors | 31 | 1990 | 896 |
Why?
|
Phenotype | 26 | 1995 | 303 |
Why?
|
Cardiology | 4 | 1991 | 25 |
Why?
|
Recurrence | 26 | 1997 | 261 |
Why?
|
Echocardiography | 11 | 2000 | 93 |
Why?
|
Romano-Ward Syndrome | 5 | 2007 | 7 |
Why?
|
Potassium Channels | 8 | 2002 | 33 |
Why?
|
Cardiovascular Diseases | 9 | 2001 | 127 |
Why?
|
Sensitivity and Specificity | 20 | 1998 | 427 |
Why?
|
Multivariate Analysis | 19 | 1995 | 225 |
Why?
|
Severity of Illness Index | 19 | 2001 | 358 |
Why?
|
Ventricular Function | 4 | 1995 | 23 |
Why?
|
Multicenter Studies as Topic | 8 | 2001 | 70 |
Why?
|
Survival Rate | 21 | 2000 | 250 |
Why?
|
Predictive Value of Tests | 18 | 1994 | 321 |
Why?
|
Heart Ventricles | 12 | 1990 | 86 |
Why?
|
Magnetic Resonance Imaging | 4 | 2006 | 294 |
Why?
|
Bundle-Branch Block | 6 | 2003 | 17 |
Why?
|
Sex Factors | 13 | 1995 | 284 |
Why?
|
Aza Compounds | 3 | 2008 | 13 |
Why?
|
Retrospective Studies | 21 | 1998 | 653 |
Why?
|
Adolescent | 40 | 1986 | 891 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2002 | 34 |
Why?
|
Quinolines | 3 | 2008 | 26 |
Why?
|
Biological Markers | 16 | 2000 | 262 |
Why?
|
Kaplan-Meier Estimate | 17 | 2007 | 89 |
Why?
|
Anti-Infective Agents | 3 | 2008 | 54 |
Why?
|
Air Pollutants | 6 | 2001 | 42 |
Why?
|
Heterozygote | 10 | 1998 | 80 |
Why?
|
Mutation, Missense | 5 | 2002 | 59 |
Why?
|
Prospective Studies | 29 | 1999 | 545 |
Why?
|
Angina, Unstable | 6 | 1994 | 20 |
Why?
|
Registries | 20 | 1998 | 83 |
Why?
|
Societies, Medical | 5 | 2001 | 90 |
Why?
|
European Continental Ancestry Group | 5 | 2006 | 117 |
Why?
|
Glomerular Filtration Rate | 2 | 2006 | 33 |
Why?
|
Carbon | 4 | 2004 | 30 |
Why?
|
Research Design | 5 | 2002 | 169 |
Why?
|
Muscle Proteins | 2 | 2008 | 56 |
Why?
|
Environmental Exposure | 3 | 2004 | 75 |
Why?
|
Cholesterol Ester Transfer Proteins | 2 | 2007 | 9 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2011 | 4 |
Why?
|
Heart Failure, Diastolic | 1 | 2011 | 2 |
Why?
|
Cohort Studies | 14 | 1994 | 332 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2001 | 78 |
Why?
|
Lipoproteins | 4 | 2001 | 52 |
Why?
|
Reproducibility of Results | 15 | 1998 | 391 |
Why?
|
Sequence Deletion | 2 | 2007 | 88 |
Why?
|
Child | 28 | 1994 | 749 |
Why?
|
Posture | 1 | 2010 | 68 |
Why?
|
Exercise | 4 | 2001 | 82 |
Why?
|
Practice Guidelines as Topic | 6 | 2007 | 174 |
Why?
|
von Willebrand Factor | 4 | 1999 | 34 |
Why?
|
Periodicals as Topic | 1 | 2011 | 41 |
Why?
|
African Continental Ancestry Group | 3 | 2006 | 80 |
Why?
|
C-Reactive Protein | 9 | 2002 | 54 |
Why?
|
United States | 20 | 1991 | 604 |
Why?
|
Air Pollution | 4 | 2005 | 17 |
Why?
|
Terminology as Topic | 2 | 2006 | 81 |
Why?
|
Hospitalization | 7 | 2004 | 169 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2008 | 6 |
Why?
|
Ventricular Dysfunction | 1 | 2008 | 8 |
Why?
|
Lipids | 10 | 1999 | 97 |
Why?
|
Young Adult | 14 | 2008 | 380 |
Why?
|
Cation Transport Proteins | 3 | 2002 | 17 |
Why?
|
Kidney Diseases | 2 | 2009 | 90 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2005 | 29 |
Why?
|
Obesity | 3 | 2000 | 149 |
Why?
|
Hypertension | 3 | 2003 | 161 |
Why?
|
Smoking | 3 | 2000 | 153 |
Why?
|
Hyperglycemia | 1 | 2008 | 31 |
Why?
|
Physicians | 2 | 2005 | 104 |
Why?
|
Child, Preschool | 19 | 1995 | 554 |
Why?
|
Angiotensinogen | 1 | 2006 | 8 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2007 | 39 |
Why?
|
Incidence | 11 | 2006 | 336 |
Why?
|
Particulate Matter | 5 | 2006 | 22 |
Why?
|
Regression Analysis | 11 | 1994 | 256 |
Why?
|
Mental Health | 1 | 2007 | 43 |
Why?
|
Ventricular Function, Left | 6 | 2005 | 41 |
Why?
|
Comorbidity | 9 | 1999 | 190 |
Why?
|
Models, Biological | 2 | 2011 | 410 |
Why?
|
Attitude of Health Personnel | 2 | 2005 | 165 |
Why?
|
Heart | 7 | 1995 | 88 |
Why?
|
Models, Economic | 1 | 2005 | 14 |
Why?
|
DNA | 1 | 2011 | 262 |
Why?
|
Diabetes Mellitus | 2 | 2001 | 72 |
Why?
|
Angioplasty, Balloon | 1 | 2006 | 35 |
Why?
|
Circadian Rhythm | 2 | 2004 | 50 |
Why?
|
Gonadal Steroid Hormones | 1 | 2005 | 30 |
Why?
|
Telemedicine | 1 | 2005 | 11 |
Why?
|
Probability | 9 | 2001 | 190 |
Why?
|
Public Opinion | 1 | 2005 | 12 |
Why?
|
Age Factors | 10 | 1995 | 480 |
Why?
|
Trans-Activators | 3 | 2002 | 113 |
Why?
|
Infant | 14 | 1995 | 464 |
Why?
|
Critical Illness | 1 | 2005 | 34 |
Why?
|
Aged, 80 and over | 13 | 2004 | 599 |
Why?
|
Tachycardia, Supraventricular | 3 | 1990 | 14 |
Why?
|
Health Care Costs | 1 | 2005 | 73 |
Why?
|
Choice Behavior | 1 | 2005 | 34 |
Why?
|
Sex Distribution | 8 | 2003 | 101 |
Why?
|
Sequence Analysis, Protein | 1 | 2003 | 14 |
Why?
|
Risk | 7 | 2004 | 203 |
Why?
|
Cholesterol, HDL | 4 | 2003 | 26 |
Why?
|
Cause of Death | 7 | 2001 | 82 |
Why?
|
Steroids | 1 | 2004 | 38 |
Why?
|
Reference Values | 6 | 1999 | 278 |
Why?
|
DNA-Binding Proteins | 3 | 2002 | 204 |
Why?
|
Pirenzepine | 1 | 2003 | 4 |
Why?
|
Jervell-Lange Nielsen Syndrome | 3 | 2002 | 5 |
Why?
|
Chi-Square Distribution | 13 | 1999 | 179 |
Why?
|
Haloperidol | 1 | 2003 | 16 |
Why?
|
Sequence Alignment | 1 | 2003 | 114 |
Why?
|
Autonomic Nervous System | 5 | 2001 | 41 |
Why?
|
Particle Size | 9 | 2002 | 55 |
Why?
|
Myocardium | 3 | 2006 | 119 |
Why?
|
Statistics, Nonparametric | 10 | 2001 | 141 |
Why?
|
Logistic Models | 11 | 2000 | 251 |
Why?
|
Drug Approval | 1 | 2002 | 15 |
Why?
|
Inflammation | 6 | 2002 | 208 |
Why?
|
Age Distribution | 8 | 2003 | 127 |
Why?
|
Electrophysiology | 9 | 1994 | 101 |
Why?
|
Antipsychotic Agents | 1 | 2003 | 49 |
Why?
|
Disease Progression | 7 | 2002 | 244 |
Why?
|
Patient Selection | 4 | 2008 | 155 |
Why?
|
Blood Urea Nitrogen | 4 | 2005 | 30 |
Why?
|
Monitoring, Physiologic | 2 | 2010 | 81 |
Why?
|
Odds Ratio | 8 | 1995 | 157 |
Why?
|
Mortality | 3 | 1997 | 50 |
Why?
|
Metabolic Syndrome X | 3 | 2003 | 34 |
Why?
|
Ion Channel Gating | 2 | 2011 | 42 |
Why?
|
Cholesterol | 3 | 1997 | 86 |
Why?
|
Biopsy | 2 | 2010 | 207 |
Why?
|
Recovery of Function | 2 | 2009 | 91 |
Why?
|
Baroreflex | 3 | 2004 | 9 |
Why?
|
Up-Regulation | 3 | 2006 | 183 |
Why?
|
Blood Pressure | 4 | 2007 | 205 |
Why?
|
Connexin 43 | 2 | 2006 | 14 |
Why?
|
Diphenhydramine | 1 | 1997 | 8 |
Why?
|
Analysis of Variance | 5 | 1994 | 339 |
Why?
|
Histamine H1 Antagonists | 1 | 1997 | 13 |
Why?
|
Evidence-Based Medicine | 2 | 2009 | 125 |
Why?
|
ROC Curve | 5 | 1998 | 80 |
Why?
|
Clinical Trials as Topic | 6 | 2002 | 251 |
Why?
|
Death | 2 | 2003 | 21 |
Why?
|
Equipment Failure | 4 | 2008 | 44 |
Why?
|
KCNQ Potassium Channels | 4 | 2002 | 9 |
Why?
|
Women's Health | 1 | 1997 | 40 |
Why?
|
Asthma | 3 | 1999 | 97 |
Why?
|
Fibrin Fibrinogen Degradation Products | 4 | 1999 | 16 |
Why?
|
Ion Channels | 8 | 1995 | 61 |
Why?
|
Hospital Mortality | 2 | 2006 | 60 |
Why?
|
New York | 6 | 2001 | 422 |
Why?
|
Phospholipases A | 2 | 2006 | 24 |
Why?
|
Angina Pectoris | 4 | 1994 | 31 |
Why?
|
Body Mass Index | 3 | 2000 | 122 |
Why?
|
Case-Control Studies | 8 | 1997 | 283 |
Why?
|
Plasminogen Activator Inhibitor 1 | 3 | 1999 | 26 |
Why?
|
Inhalation Exposure | 2 | 2007 | 22 |
Why?
|
Genetic Testing | 5 | 2003 | 49 |
Why?
|
Pregnancy Complications, Cardiovascular | 3 | 1998 | 28 |
Why?
|
Hemodynamics | 2 | 2002 | 131 |
Why?
|
DNA Mutational Analysis | 4 | 2002 | 110 |
Why?
|
Databases, Factual | 2 | 2005 | 102 |
Why?
|
Prevalence | 3 | 2003 | 281 |
Why?
|
Ventricular Remodeling | 2 | 2011 | 21 |
Why?
|
Coronary Vessels | 2 | 2004 | 53 |
Why?
|
Canada | 3 | 2007 | 60 |
Why?
|
Blood Glucose | 3 | 2001 | 99 |
Why?
|
Flecainide | 2 | 2001 | 8 |
Why?
|
Testosterone | 2 | 2004 | 57 |
Why?
|
Convalescence | 3 | 1994 | 15 |
Why?
|
Pedigree | 3 | 2002 | 84 |
Why?
|
Equipment Design | 3 | 2006 | 132 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 1999 | 224 |
Why?
|
Dose-Response Relationship, Drug | 3 | 1997 | 431 |
Why?
|
Ventricular Dysfunction, Right | 2 | 2009 | 11 |
Why?
|
Age of Onset | 3 | 2001 | 64 |
Why?
|
Japan | 2 | 2007 | 25 |
Why?
|
Combined Modality Therapy | 4 | 1986 | 219 |
Why?
|
Thrombosis | 4 | 1999 | 105 |
Why?
|
Serum Amyloid A Protein | 4 | 2002 | 15 |
Why?
|
Ventricular Function, Right | 3 | 2005 | 15 |
Why?
|
Cross-Over Studies | 2 | 2009 | 82 |
Why?
|
Cardiomyopathies | 3 | 2003 | 43 |
Why?
|
Survivors | 2 | 2006 | 45 |
Why?
|
Emotions | 2 | 2001 | 58 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2011 | 5 |
Why?
|
Referral and Consultation | 2 | 2010 | 134 |
Why?
|
Hemostasis | 2 | 1999 | 44 |
Why?
|
Genetic Variation | 2 | 2008 | 91 |
Why?
|
Cardiotoxins | 1 | 2011 | 3 |
Why?
|
Guideline Adherence | 2 | 2008 | 64 |
Why?
|
Journal Impact Factor | 1 | 2011 | 3 |
Why?
|
Menopause | 1 | 2011 | 27 |
Why?
|
Neuromuscular Nondepolarizing Agents | 1 | 2011 | 10 |
Why?
|
Drug Therapy, Combination | 2 | 2008 | 189 |
Why?
|
Tachycardia, Paroxysmal | 1 | 2010 | 6 |
Why?
|
Enalapril | 1 | 2010 | 6 |
Why?
|
Aldosterone Antagonists | 1 | 2010 | 6 |
Why?
|
Myocardial Contraction | 1 | 2011 | 52 |
Why?
|
Spironolactone | 1 | 2010 | 9 |
Why?
|
Language | 1 | 2011 | 23 |
Why?
|
Databases, Genetic | 1 | 2010 | 20 |
Why?
|
Pattern Recognition, Automated | 2 | 2005 | 19 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 65 |
Why?
|
Electrodes, Implanted | 1 | 2011 | 31 |
Why?
|
Diagnosis, Differential | 3 | 2000 | 402 |
Why?
|
Gene Frequency | 2 | 2006 | 42 |
Why?
|
Societies, Nursing | 1 | 2010 | 1 |
Why?
|
Cardiology Service, Hospital | 1 | 2010 | 5 |
Why?
|
Heavy Ions | 1 | 2010 | 2 |
Why?
|
Guidelines as Topic | 1 | 2011 | 77 |
Why?
|
Adrenergic beta-Agonists | 2 | 1999 | 39 |
Why?
|
Reference Standards | 1 | 2010 | 35 |
Why?
|
Primary Prevention | 2 | 2007 | 44 |
Why?
|
Hypertriglyceridemia | 2 | 2006 | 14 |
Why?
|
Life Change Events | 1 | 2010 | 50 |
Why?
|
Confidence Intervals | 2 | 2007 | 104 |
Why?
|
Hospital Units | 1 | 2010 | 20 |
Why?
|
Acute Coronary Syndrome | 1 | 2009 | 4 |
Why?
|
Blood Coagulation Factors | 4 | 2000 | 31 |
Why?
|
Forecasting | 3 | 1998 | 147 |
Why?
|
Internet | 2 | 2007 | 64 |
Why?
|
Disease-Free Survival | 3 | 2001 | 102 |
Why?
|
Magnetic Resonance Angiography | 1 | 2010 | 32 |
Why?
|
Physician's Practice Patterns | 2 | 2008 | 149 |
Why?
|
Radiation Dosage | 1 | 2010 | 65 |
Why?
|
Critical Care | 1 | 2010 | 34 |
Why?
|
Happiness | 1 | 2009 | 11 |
Why?
|
Silicones | 1 | 2009 | 20 |
Why?
|
Lipase | 1 | 2008 | 11 |
Why?
|
Hemostasis, Surgical | 1 | 2008 | 11 |
Why?
|
Statistics as Topic | 3 | 2001 | 133 |
Why?
|
Tachycardia | 2 | 1986 | 32 |
Why?
|
Apolipoprotein A-I | 1 | 2008 | 19 |
Why?
|
Punctures | 1 | 2008 | 22 |
Why?
|
Coagulants | 1 | 2008 | 12 |
Why?
|
Acetanilides | 1 | 2008 | 6 |
Why?
|
Vagus Nerve | 1 | 2008 | 25 |
Why?
|
Double-Blind Method | 2 | 2005 | 274 |
Why?
|
Lipoprotein(a) | 1 | 2008 | 12 |
Why?
|
Conserved Sequence | 1 | 2009 | 73 |
Why?
|
Coronary Angiography | 3 | 1998 | 49 |
Why?
|
Asian Continental Ancestry Group | 1 | 2008 | 23 |
Why?
|
Diagnostic Errors | 1 | 2009 | 73 |
Why?
|
Siblings | 1 | 2008 | 28 |
Why?
|
Chromatography, High Pressure Liquid | 3 | 2002 | 121 |
Why?
|
Hypercholesterolemia | 2 | 2005 | 33 |
Why?
|
Femoral Artery | 1 | 2008 | 52 |
Why?
|
Delayed Rectifier Potassium Channels | 1 | 2008 | 8 |
Why?
|
Atrial Flutter | 1 | 2008 | 11 |
Why?
|
Coronary Stenosis | 2 | 2004 | 6 |
Why?
|
Fractals | 3 | 2001 | 5 |
Why?
|
Triglycerides | 2 | 2003 | 48 |
Why?
|
Cost-Benefit Analysis | 2 | 2005 | 118 |
Why?
|
Discriminant Analysis | 1 | 2007 | 21 |
Why?
|
Piperazines | 1 | 2008 | 57 |
Why?
|
Medical History Taking | 1 | 2008 | 53 |
Why?
|
Quality of Life | 2 | 2007 | 188 |
Why?
|
Catheter Ablation | 1 | 2009 | 38 |
Why?
|
Israel | 1 | 2007 | 20 |
Why?
|
African Americans | 1 | 2010 | 108 |
Why?
|
Aryldialkylphosphatase | 1 | 2007 | 6 |
Why?
|
Postoperative Complications | 2 | 2001 | 305 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2007 | 8 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2007 | 5 |
Why?
|
Sodium | 1 | 2008 | 96 |
Why?
|
Pregnancy, High-Risk | 1 | 2007 | 12 |
Why?
|
Cardiac Output, Low | 1 | 2007 | 9 |
Why?
|
Patient Education as Topic | 2 | 2005 | 128 |
Why?
|
E-Selectin | 1 | 2006 | 12 |
Why?
|
Aging | 2 | 1998 | 275 |
Why?
|
International Normalized Ratio | 1 | 2006 | 8 |
Why?
|
Vehicle Emissions | 1 | 2007 | 14 |
Why?
|
Infant, Newborn | 5 | 2007 | 389 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2010 | 145 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 24 |
Why?
|
Hemorrhage | 1 | 2008 | 103 |
Why?
|
Radiotherapy, High-Energy | 1 | 2006 | 16 |
Why?
|
Threonine | 1 | 2006 | 27 |
Why?
|
NADPH Oxidase | 1 | 2007 | 21 |
Why?
|
User-Computer Interface | 1 | 2007 | 36 |
Why?
|
Kidney | 1 | 2010 | 223 |
Why?
|
Methionine | 1 | 2006 | 38 |
Why?
|
Hypolipidemic Agents | 2 | 2002 | 17 |
Why?
|
Protein Precursors | 1 | 2007 | 48 |
Why?
|
Education, Medical, Continuing | 1 | 2007 | 54 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2007 | 31 |
Why?
|
Point Mutation | 2 | 2003 | 122 |
Why?
|
Homozygote | 1 | 2006 | 68 |
Why?
|
Rest | 1 | 2006 | 21 |
Why?
|
Myocardial Revascularization | 1 | 2006 | 18 |
Why?
|
Surgical Procedures, Elective | 1 | 2006 | 31 |
Why?
|
Pregnancy Outcome | 1 | 2007 | 54 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2005 | 11 |
Why?
|
Health Personnel | 1 | 2006 | 54 |
Why?
|
Heart Function Tests | 2 | 2001 | 14 |
Why?
|
Outcome Assessment (Health Care) | 2 | 2005 | 163 |
Why?
|
Arousal | 2 | 2000 | 37 |
Why?
|
Paper | 1 | 2005 | 8 |
Why?
|
Stress, Psychological | 1 | 2009 | 117 |
Why?
|
Information Storage and Retrieval | 1 | 2005 | 19 |
Why?
|
Poland | 1 | 2005 | 6 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2005 | 8 |
Why?
|
Epidemiologic Studies | 1 | 2005 | 19 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2006 | 51 |
Why?
|
Zinc Oxide | 1 | 2005 | 8 |
Why?
|
Follicle Stimulating Hormone | 1 | 2005 | 36 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 25 |
Why?
|
Apolipoproteins B | 2 | 2000 | 18 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 34 |
Why?
|
Diabetes Complications | 1 | 2005 | 49 |
Why?
|
Insulin | 3 | 1999 | 129 |
Why?
|
Heart Rupture, Post-Infarction | 1 | 2004 | 2 |
Why?
|
Peptide Fragments | 1 | 2007 | 144 |
Why?
|
Prostheses and Implants | 1 | 2005 | 47 |
Why?
|
Contrast Media | 1 | 2007 | 116 |
Why?
|
Software | 1 | 2005 | 92 |
Why?
|
Molecular Sequence Data | 3 | 2002 | 404 |
Why?
|
Postoperative Period | 1 | 2004 | 63 |
Why?
|
Intermittent Claudication | 1 | 2004 | 7 |
Why?
|
Sympathectomy | 1 | 2004 | 11 |
Why?
|
Germany | 3 | 2005 | 21 |
Why?
|
Amino Acid Sequence | 2 | 2003 | 319 |
Why?
|
Heterozygote Detection | 2 | 1999 | 16 |
Why?
|
Genes, Recessive | 1 | 2003 | 33 |
Why?
|
Endpoint Determination | 1 | 2003 | 27 |
Why?
|
Primary Health Care | 1 | 2008 | 151 |
Why?
|
Thioridazine | 1 | 2003 | 2 |
Why?
|
Risk Sharing, Financial | 1 | 2003 | 4 |
Why?
|
Estradiol | 1 | 2004 | 78 |
Why?
|
Drug Labeling | 1 | 2003 | 12 |
Why?
|
Dopamine Antagonists | 1 | 2003 | 11 |
Why?
|
Benzodiazepines | 1 | 2003 | 22 |
Why?
|
Hyperlipidemias | 1 | 2003 | 42 |
Why?
|
Lipoproteins, HDL | 2 | 1997 | 21 |
Why?
|
Atropine | 1 | 2002 | 25 |
Why?
|
Apolipoproteins | 4 | 2000 | 19 |
Why?
|
Androgens | 1 | 2004 | 38 |
Why?
|
History, 20th Century | 2 | 1991 | 111 |
Why?
|
Exercise Test | 3 | 1994 | 51 |
Why?
|
United States Food and Drug Administration | 1 | 2002 | 28 |
Why?
|
Oxidoreductases Acting on CH-NH Group Donors | 1 | 2001 | 3 |
Why?
|
Hyperhomocysteinemia | 1 | 2001 | 4 |
Why?
|
Leukocyte Count | 1 | 2001 | 94 |
Why?
|
Blood Proteins | 1 | 2001 | 71 |
Why?
|
Cardiolipins | 1 | 2000 | 7 |
Why?
|
Sex Characteristics | 2 | 1998 | 85 |
Why?
|
Gene Expression Profiling | 1 | 2003 | 138 |
Why?
|
Endothelium, Vascular | 2 | 2001 | 139 |
Why?
|
Models, Molecular | 3 | 2002 | 102 |
Why?
|
Longitudinal Studies | 2 | 1997 | 195 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2001 | 58 |
Why?
|
Electroencephalography | 1 | 2000 | 88 |
Why?
|
Autoantibodies | 1 | 2000 | 64 |
Why?
|
Latex Fixation Tests | 1 | 1999 | 15 |
Why?
|
Swimming | 1 | 1999 | 6 |
Why?
|
Questionnaires | 1 | 2005 | 360 |
Why?
|
Spain | 2 | 2008 | 10 |
Why?
|
Polymorphism, Single-Stranded Conformational | 3 | 2002 | 23 |
Why?
|
Acoustic Stimulation | 1 | 1999 | 49 |
Why?
|
Creatinine | 2 | 2007 | 69 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2006 | 9 |
Why?
|
Overdose | 1 | 1997 | 16 |
Why?
|
Codon, Nonsense | 2 | 2007 | 15 |
Why?
|
Models, Animal | 2 | 2006 | 85 |
Why?
|
Physicians, Family | 2 | 2008 | 66 |
Why?
|
Systole | 2 | 2005 | 31 |
Why?
|
Lipoproteins, LDL | 1 | 1997 | 20 |
Why?
|
Membrane Potentials | 2 | 2007 | 99 |
Why?
|
Phospholipases A2 | 2 | 2006 | 16 |
Why?
|
Action Potentials | 2 | 1990 | 77 |
Why?
|
Family Health | 3 | 1998 | 69 |
Why?
|
Amiodarone | 2 | 2002 | 10 |
Why?
|
Rabbits | 2 | 2006 | 252 |
Why?
|
Cerebrovascular Disorders | 1 | 1997 | 66 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 1995 | 13 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 1995 | 21 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 1995 | 19 |
Why?
|
Life Tables | 2 | 2004 | 33 |
Why?
|
Administration, Inhalation | 2 | 2005 | 60 |
Why?
|
Genetic Markers | 2 | 2003 | 78 |
Why?
|
Pregnancy | 3 | 1998 | 455 |
Why?
|
Suicide, Attempted | 1 | 1997 | 42 |
Why?
|
Sputum | 2 | 2004 | 26 |
Why?
|
Metoprolol | 2 | 2000 | 7 |
Why?
|
Atenolol | 2 | 2000 | 10 |
Why?
|
Nitric Oxide | 2 | 2004 | 85 |
Why?
|
Blood Coagulation | 2 | 2000 | 57 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 8 |
Why?
|
Sequence Analysis, DNA | 2 | 2002 | 110 |
Why?
|
Nonlinear Dynamics | 2 | 2001 | 18 |
Why?
|
Glucose Tolerance Test | 1 | 2011 | 24 |
Why?
|
Animals | 4 | 2006 | 1031 |
Why?
|
Echocardiography, Doppler | 1 | 2011 | 20 |
Why?
|
Estrogen Replacement Therapy | 1 | 2011 | 21 |
Why?
|
Europe | 1 | 2011 | 54 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2001 | 45 |
Why?
|
Computers, Handheld | 1 | 2010 | 7 |
Why?
|
Environmental Monitoring | 1 | 2011 | 28 |
Why?
|
Minnesota | 1 | 2010 | 22 |
Why?
|
Climate | 1 | 2010 | 6 |
Why?
|
Atmosphere | 1 | 2010 | 3 |
Why?
|
Blood Volume | 1 | 2010 | 35 |
Why?
|
Endocardium | 1 | 2010 | 8 |
Why?
|
World Health | 1 | 2011 | 41 |
Why?
|
RNA, Messenger | 2 | 2006 | 394 |
Why?
|
Desmosomes | 1 | 2010 | 4 |
Why?
|
Polymerase Chain Reaction | 2 | 2003 | 279 |
Why?
|
Xenopus laevis | 1 | 2011 | 49 |
Why?
|
Oocytes | 1 | 2011 | 45 |
Why?
|
Temperature | 1 | 2010 | 137 |
Why?
|
Obesity, Morbid | 1 | 2010 | 28 |
Why?
|
Protein Structure, Secondary | 1 | 2009 | 54 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2010 | 85 |
Why?
|
Causality | 1 | 2009 | 42 |
Why?
|
Early Ambulation | 1 | 2008 | 4 |
Why?
|
Computer Simulation | 1 | 2011 | 134 |
Why?
|
Continental Population Groups | 1 | 2010 | 85 |
Why?
|
Fibrinogen | 2 | 1999 | 45 |
Why?
|
Angiography | 1 | 2009 | 63 |
Why?
|
Administration, Topical | 1 | 2008 | 57 |
Why?
|
Health Care Surveys | 1 | 2010 | 91 |
Why?
|
Decision Support Systems, Clinical | 1 | 2008 | 9 |
Why?
|
Pressure | 1 | 2008 | 79 |
Why?
|
Minority Groups | 1 | 2008 | 38 |
Why?
|
Interviews as Topic | 1 | 2009 | 94 |
Why?
|
Computational Biology | 1 | 2009 | 39 |
Why?
|
Oscillometry | 1 | 2008 | 13 |
Why?
|
Therapy, Computer-Assisted | 1 | 2008 | 8 |
Why?
|
Genetic Linkage | 2 | 1995 | 57 |
Why?
|
Chromosome Mapping | 2 | 1995 | 107 |
Why?
|
Patient Satisfaction | 1 | 2009 | 120 |
Why?
|
Frameshift Mutation | 1 | 2007 | 20 |
Why?
|
RNA Splice Sites | 1 | 2007 | 14 |
Why?
|
Netherlands | 1 | 2007 | 16 |
Why?
|
Mutagenesis, Insertional | 1 | 2007 | 37 |
Why?
|
Ion Transport | 1 | 2007 | 42 |
Why?
|
Sulfur Dioxide | 1 | 2006 | 5 |
Why?
|
Rats, Inbred SHR | 1 | 2007 | 24 |
Why?
|
Patient Readmission | 1 | 2007 | 23 |
Why?
|
Postpartum Period | 1 | 2007 | 32 |
Why?
|
Injections, Intraperitoneal | 1 | 2007 | 57 |
Why?
|
Automobile Driving | 1 | 2007 | 19 |
Why?
|
Aspartic Acid | 1 | 2007 | 37 |
Why?
|
Telemetry | 1 | 2007 | 19 |
Why?
|
Parity | 1 | 2007 | 28 |
Why?
|
Glutamine | 1 | 2007 | 27 |
Why?
|
Carbon Monoxide | 1 | 2006 | 24 |
Why?
|
Internationality | 1 | 2006 | 28 |
Why?
|
Aerosols | 1 | 2007 | 39 |
Why?
|
Nitrous Oxide | 1 | 2006 | 18 |
Why?
|
Patient Admission | 1 | 2007 | 72 |
Why?
|
Protein Transport | 1 | 2007 | 101 |
Why?
|
Arginine | 1 | 2007 | 57 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 68 |
Why?
|
Glutamic Acid | 1 | 2007 | 66 |
Why?
|
Potassium | 1 | 2007 | 98 |
Why?
|
Nebraska | 1 | 2005 | 6 |
Why?
|
Models, Cardiovascular | 1 | 2006 | 40 |
Why?
|
Gestational Age | 1 | 2007 | 114 |
Why?
|
Gap Junctions | 1 | 2006 | 15 |
Why?
|
Propanolamines | 1 | 2005 | 12 |
Why?
|
Database Management Systems | 1 | 2005 | 11 |
Why?
|
Placebo Effect | 1 | 2005 | 26 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 216 |
Why?
|
Carbazoles | 1 | 2005 | 21 |
Why?
|
Artificial Intelligence | 1 | 2005 | 16 |
Why?
|
Equipment Failure Analysis | 1 | 2005 | 44 |
Why?
|
Length of Stay | 1 | 2007 | 166 |
Why?
|
Massachusetts | 1 | 2005 | 22 |
Why?
|
Lipopolysaccharides | 1 | 2007 | 98 |
Why?
|
Advisory Committees | 1 | 2005 | 17 |
Why?
|
Protein Structure, Tertiary | 1 | 2007 | 163 |
Why?
|
Radiotherapy | 1 | 2006 | 73 |
Why?
|
Smoking Cessation | 1 | 2006 | 46 |
Why?
|
Lymphocyte Subsets | 1 | 2004 | 26 |
Why?
|
Heart Atria | 1 | 2005 | 37 |
Why?
|
Respiratory System | 1 | 2005 | 30 |
Why?
|
Ganglionectomy | 1 | 2004 | 3 |
Why?
|
Cardiovascular System | 1 | 2004 | 40 |
Why?
|
Respiration | 1 | 2004 | 78 |
Why?
|
Blotting, Western | 1 | 2006 | 275 |
Why?
|
Blood Chemical Analysis | 1 | 2003 | 34 |
Why?
|
Factor Analysis, Statistical | 1 | 2003 | 45 |
Why?
|
Rare Diseases | 1 | 2003 | 15 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 243 |
Why?
|
Diseases in Twins | 1 | 2003 | 30 |
Why?
|
Nucleic Acid Denaturation | 1 | 2003 | 21 |
Why?
|
Entropy | 1 | 2002 | 7 |
Why?
|
Oxidative Stress | 1 | 2007 | 119 |
Why?
|
Clinical Protocols | 1 | 2003 | 93 |
Why?
|
Exons | 1 | 2003 | 91 |
Why?
|
Introns | 1 | 2003 | 58 |
Why?
|
Immunohistochemistry | 1 | 2006 | 355 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2002 | 18 |
Why?
|
Principal Component Analysis | 1 | 2001 | 18 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2001 | 5 |
Why?
|
Mexiletine | 1 | 2001 | 8 |
Why?
|
Drug Monitoring | 1 | 2001 | 33 |
Why?
|
beta 2-Glycoprotein I | 1 | 2000 | 4 |
Why?
|
Sleep | 1 | 2001 | 31 |
Why?
|
Mitral Valve Insufficiency | 1 | 2000 | 19 |
Why?
|
Cytokines | 1 | 2004 | 207 |
Why?
|
Nadolol | 1 | 2000 | 5 |
Why?
|
Immunoglobulin M | 1 | 2000 | 81 |
Why?
|
Administration, Oral | 1 | 2001 | 170 |
Why?
|
Propranolol | 1 | 2000 | 34 |
Why?
|
Bias (Epidemiology) | 1 | 2000 | 35 |
Why?
|
Automation | 1 | 1999 | 27 |
Why?
|
Factor VII | 1 | 1999 | 10 |
Why?
|
Family | 1 | 2001 | 101 |
Why?
|
Factor VIIa | 1 | 1999 | 12 |
Why?
|
Pilot Projects | 1 | 2001 | 264 |
Why?
|
Evaluation Studies as Topic | 1 | 1999 | 178 |
Why?
|
Binding Sites | 1 | 2002 | 213 |
Why?
|
Chronic Disease | 1 | 2001 | 267 |
Why?
|
Stress, Physiological | 1 | 2000 | 76 |
Why?
|
Glycoproteins | 1 | 2000 | 113 |
Why?
|
Rats | 1 | 2007 | 530 |
Why?
|
International Cooperation | 1 | 1998 | 42 |
Why?
|
Abortion, Induced | 1 | 1998 | 26 |
Why?
|
Acute Disease | 1 | 2000 | 271 |
Why?
|
Immunoglobulin G | 1 | 2000 | 191 |
Why?
|
Thallium Radioisotopes | 1 | 1997 | 12 |
Why?
|
Base Sequence | 1 | 2002 | 371 |
Why?
|
Gene Expression | 1 | 2000 | 291 |
Why?
|
Arrhythmia, Sinus | 1 | 1995 | 6 |
Why?
|
